SG11202100338PA - Imidazo[1,2-b]pyridazines as trk inhibitors - Google Patents

Imidazo[1,2-b]pyridazines as trk inhibitors

Info

Publication number
SG11202100338PA
SG11202100338PA SG11202100338PA SG11202100338PA SG11202100338PA SG 11202100338P A SG11202100338P A SG 11202100338PA SG 11202100338P A SG11202100338P A SG 11202100338PA SG 11202100338P A SG11202100338P A SG 11202100338PA SG 11202100338P A SG11202100338P A SG 11202100338PA
Authority
SG
Singapore
Prior art keywords
pyridazines
imidazo
trk inhibitors
trk
inhibitors
Prior art date
Application number
SG11202100338PA
Inventor
Alan Brown
Angela Glen
Original Assignee
Benevolentai Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benevolentai Bio Ltd filed Critical Benevolentai Bio Ltd
Publication of SG11202100338PA publication Critical patent/SG11202100338PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202100338PA 2018-08-23 2019-08-23 Imidazo[1,2-b]pyridazines as trk inhibitors SG11202100338PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1813791.9A GB201813791D0 (en) 2018-08-23 2018-08-23 Organic compounds
PCT/GB2019/052378 WO2020039209A1 (en) 2018-08-23 2019-08-23 Imidazo[1,2-b]pyridazines as trk inhibitors

Publications (1)

Publication Number Publication Date
SG11202100338PA true SG11202100338PA (en) 2021-03-30

Family

ID=63715095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100338PA SG11202100338PA (en) 2018-08-23 2019-08-23 Imidazo[1,2-b]pyridazines as trk inhibitors

Country Status (20)

Country Link
US (1) US20210253572A1 (en)
EP (1) EP3840832B1 (en)
JP (1) JP7417594B2 (en)
KR (1) KR20210049089A (en)
CN (1) CN112805062B (en)
AU (1) AU2019325375A1 (en)
BR (1) BR112021003026A2 (en)
CA (1) CA3106431A1 (en)
DK (1) DK3840832T3 (en)
EA (1) EA202190323A1 (en)
ES (1) ES2968695T3 (en)
FI (1) FI3840832T3 (en)
GB (1) GB201813791D0 (en)
IL (1) IL280513B1 (en)
MA (1) MA53432A (en)
MX (1) MX2021002051A (en)
PL (1) PL3840832T3 (en)
PT (1) PT3840832T (en)
SG (1) SG11202100338PA (en)
WO (1) WO2020039209A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511170A (en) * 2020-01-22 2023-03-16 ベネボレントエーアイ バイオ リミティド Pharmaceutical composition and its use
EP4093376A1 (en) * 2020-01-22 2022-11-30 BenevolentAI Bio Limited Pharmaceutical compositions and their uses
CN112979646B (en) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 Imidazopyridine derivative
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
CN113444070A (en) * 2021-07-28 2021-09-28 深圳市真味生物科技有限公司 Preparation method for synthesizing chiral nicotine from chiral tert-butyl sulfinamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JP2007524596A (en) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド Co-crystal pharmaceutical composition
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
CN108329246B (en) 2011-05-13 2021-02-26 阵列生物制药公司 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors
BR112014014276A2 (en) 2011-12-12 2017-06-13 Dr Reddys Laboratories Ltd compound, pharmaceutical composition, method for inhibiting a receptor kinase, and methods for treating conditions, diseases and / or disorders, and pain
JP6160613B2 (en) 2012-04-26 2017-07-12 小野薬品工業株式会社 Trk inhibitory compound
WO2014175370A1 (en) 2013-04-25 2014-10-30 塩野義製薬株式会社 Pyrrolidine derivative and pharmaceutical composition containing same
JP7321183B2 (en) 2017-12-15 2023-08-04 ピラミッド バイオサイエンシズ インコーポレイテッド 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5] as TRK kinase inhibitors for treating cancer -A] pyrimidine derivatives and related compounds
GB201811825D0 (en) * 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds

Also Published As

Publication number Publication date
IL280513B1 (en) 2024-07-01
JP2021535125A (en) 2021-12-16
ES2968695T3 (en) 2024-05-13
PL3840832T3 (en) 2024-03-25
FI3840832T3 (en) 2024-01-12
WO2020039209A1 (en) 2020-02-27
KR20210049089A (en) 2021-05-04
EP3840832B1 (en) 2023-10-11
CN112805062B (en) 2024-06-04
CA3106431A1 (en) 2020-02-27
DK3840832T3 (en) 2024-01-15
CN112805062A (en) 2021-05-14
BR112021003026A2 (en) 2021-05-11
JP7417594B2 (en) 2024-01-18
IL280513A (en) 2021-03-01
GB201813791D0 (en) 2018-10-10
PT3840832T (en) 2024-01-15
MX2021002051A (en) 2021-06-23
MA53432A (en) 2021-06-30
US20210253572A1 (en) 2021-08-19
AU2019325375A1 (en) 2021-02-04
EP3840832A1 (en) 2021-06-30
EA202190323A1 (en) 2021-05-28

Similar Documents

Publication Publication Date Title
ZA201905456B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL284228A (en) Imidazo[1,2-b]pyridazine il-17a inhibitors
IL277576A (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL265918B (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL280513B1 (en) Imidazo[1,2-b]pyridazines as trk inhibitors
EP3452481A4 (en) SUBSTITUTED IMIDAZO[1,2-b
IL290419A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
IL272988A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL269214B (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
IL280122A (en) Imidazo[1,2-b]pyridazine derivatives as trk inhibitors